CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
  
  OVERVIEW OF ACTIVITY
  Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
  
  These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer and lymphomas and chronic lymphocytic leukemia to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and refer appropriate patients for study participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investi-gational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Jeremy Abramson, MD
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Allogene Therapeutics, Celgene Corporation, EMD Serono Inc, Genentech, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, MorphoSys, Novartis, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.
  
  Deborah K Armstrong, MD
  Professor of Oncology
  Professor of Gynecology and Obstetrics
  Skip Viragh Outpatient Cancer Building
  Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  Baltimore, Maryland
  
  Advisory Committee: Cue Biopharma, Eisai Inc; Contracted Research: Advaxis Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Pfizer Inc, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Johanna Bendell, MD
  Chief Development Officer
  Director, Drug Development Unit Nashville
  Sarah Cannon Research Institute
  Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board: Five Prime Therapeutics Inc.
  
  Courtney D DiNardo, MD, MSCE
  Associate Professor, Department of Leukemia
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Jazz Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Notable.
  
  Charles E Geyer Jr, MD
  Deputy Director
  Houston Methodist Cancer Center
  Houston, Texas
  
  Advisory Committee (Uncompensated): Daiichi Sankyo Inc, Genentech, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Genentech, Roche Laboratories Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, Roche Laboratories Inc; Writing Assistance: AbbVie Inc, Genentech, Roche Laboratories Inc.
  
  Ian E Krop, MD, PhD
  Associate Chief, Division of Breast Oncology
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Context Therapeutics, Daiichi Sankyo Inc, Genentech, MacroGenics Inc, Roche Laboratories Inc, Taiho Oncology Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.
  
  Ann S LaCasce, MD, MMSc
  Program Director, Fellowship in Hematology/Oncology
  Associate Professor of Medicine
  Harvard Medical School
  Institute Physician
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantage Pharmaceuticals, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board/Committee: Amgen Inc, Incyte Corporation, Lilly, SWOG.
  
  Joyce F Liu, MD, MPH
  Assistant Professor of Medicine
  Harvard Medical School
  Director of Clinical Research, Division of Gynecologic Oncology
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Mersana Therapeutics, Tesaro, A GSK Company.
  
  John L Marshall, MD
  Chief, Hematology and Oncology
  Director, Ruesch Center for the Cure of GI Cancers
  Lombardi Comprehensive Cancer Center
  Georgetown University
  Washington, DC
  
  Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Indivumed GmbH, Roche Laboratories Inc, Taiho Oncology Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Merck, Roche Laboratories Inc, Taiho Oncology Inc.
  
  William K Oh, MD
  Chief, Division of Hematology and Medical Oncology
  Professor of Medicine and Urology
  Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
  Icahn School of Medicine at Mount Sinai
  Associate Director of Clinical Research
  The Tisch Cancer Institute
  Mount Sinai Health System
  New York, New York
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.
  
  Daniel P Petrylak, MD
  Professor of Internal Medicine (Medical Oncology) and Urology
  Yale University
  New Haven, Connecticut
  
  Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.
  
  Gregory J Riely, MD, PhD
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.
  
  Mitchell R Smith, MD, PhD
  Professor of Medicine
  Associate Center Director for Clinical Investigations
  Director, Division of Hematology and Oncology
  GW Cancer Center
  Washington, DC
  
  Data and Safety Monitoring Board/Committee: Eastern Cooperative Oncology Group; Speakers Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma.
  
  Richard M Stone, MD
  Chief of Staff
  Director, Translational Research, Leukemia Division
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Actinium Pharmaceuticals Inc, Amgen Inc, Astellas, BioLineRx, GEMoaB, Janssen Biotech Inc, MacroGenics Inc, Novartis, Takeda Oncology, Trovagene; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Novartis; Contracted Research: Arog Pharmaceuticals Inc, Novartis. Data and Safety Monitoring Board/Committee: Celgene Corporation.
  
  Zev Wainberg, MD, MSc
  Associate Professor, Department of Medicine
  Director, Early Phase Clinical Research Support
  Co-Director, UCLA GI Oncology Program
  Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Consulting Agreements: Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Five Prime Therapeutics Inc, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Merck; Data and Safety Monitoring Board/Committee: Array BioPharma Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology, and Tesaro, A GSK Company.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: March 2020
  Expiration date: March 2021